Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLine RxFRA:YP2 -5.79%21 Forward PE Ratio is 85.14 as of Jul. 17, 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review. Among 354 Biotechnology companies, BioLine Rx ranks worse than 282485.59% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
BioLine Rx Forward PE Ratio Related Terms
BioLine Rx Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for BioLine Rx's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLine Rx Forward PE Ratio Chart
BioLine Rx Annual Data
Trend
Forward PE Ratio
BioLine Rx Quarterly Data
2025-06
Forward PE Ratio
82.78
FRA:YP2 vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, BioLine Rx's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where BioLine Rx's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
BioLine Rx (FRA:YP2) has a Forward PE Ratio of 85.14 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BioLine Rx and its competitors. According to the industry distribution chart, BioLine Rx ranks #999999 out of 354 companies in the Biotechnology industry.
Is BioLine Rx's Forward PE Ratio too high?
BioLine Rx's current Forward PE Ratio is 85.14. The Biotechnology industry median Forward PE Ratio is 21.97. BioLine Rx's value of 85.14 is 287.5% above this industry median. Based on the distribution chart, BioLine Rx ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #999999 out of 354 companies for Forward PE Ratio. This places BioLine Rx in the lower half of its industry. The industry median Forward PE Ratio is 21.97. BioLine Rx's value of 85.14 is 287.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLine Rx's current Forward PE Ratio of 85.14 is 287.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BioLine Rx and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLine Rx's current Forward PE Ratio is 85.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Forward PE Ratio of 85.14. The current Forward PE Ratio is 85.14 and 287.5% above the Biotechnology industry median of 21.97. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Forward PE Ratio is 85.14 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score
Get the complete analysis for FRA:YP2
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:YP2 has been successfully added to your 
